{"DataElement":{"publicId":"5607585","version":"1","preferredName":"Glioblastoma iRANO Criteria Response Status","preferredDefinition":"Response status based on Glioblastoma Immunotherapy Response Assessment in Neuro-Oncology Criteria (iRANO).","longName":"GBM_IRANO_ST","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5607439","version":"1","preferredName":"Glioblastoma Immunotherapy Response Assessment in Neuro-Oncology Criteria","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)_Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC).","longName":"3049870v1.0:5607437v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3049870","version":"1","preferredName":"Glioblastoma","preferredDefinition":"A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.","longName":"C3058","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"838D91A3-8EB8-848A-E040-BB89AD433CBD","latestVersionIndicator":"Yes","beginDate":"2010-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-06","modifiedBy":"ONEDATA","dateModified":"2010-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5607437","version":"1","preferredName":"Immunotherapy Response Assessment in Neuro-Oncology Criteria","preferredDefinition":"Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC). ","longName":"C131131","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy Response Assessment in Neuro-Oncology Criteria","conceptCode":"C131131","definition":"Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44052A8D-6769-758E-E053-F662850AFE20","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44052A8D-677A-758E-E053-F662850AFE20","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"COOPERM","dateModified":"2016-12-30","changeDescription":"Created for GBM Pembro HSPPC study in C3D as requested by Y. Yakovlev. mc 12/19/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5607581","version":"1","preferredName":"iRANO Criteria Response Status","preferredDefinition":"A condition or state at a particular time.","longName":"IRANO_RESP_ST","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Progressive Disease","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"2559908","version":"1","preferredName":"Progressive Disease","longName":"2559908","preferredDefinition":"Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B711-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeDescription":"Manually Curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"44053298-D14B-7592-E053-F662850AB82F","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"},{"value":"Stable Disease","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2560100","version":"1","preferredName":"Stable Disease","longName":"2560100","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"44053298-D155-7592-E053-F662850AB82F","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"},{"value":"Minor Response","valueDescription":"Minor Response","ValueMeaning":{"publicId":"5607583","version":"1","preferredName":"Minor Response","longName":"5607583","preferredDefinition":"A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimal Response","conceptCode":"C123598","definition":"A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44053298-D162-7592-E053-F662850AB82F","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"SOKKERL","dateModified":"2023-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"44053298-D17B-7592-E053-F662850AB82F","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"},{"value":"Partial Response","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3854969","version":"1","preferredName":"Partial Remission","longName":"3854969","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86B4-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"44053298-D18F-7592-E053-F662850AB82F","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"},{"value":"Complete Response","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"44053298-D19A-7592-E053-F662850AB82F","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"ONEDATA","dateModified":"2016-12-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44053298-D136-7592-E053-F662850AB82F","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"COOPERM","dateModified":"2016-12-30","changeDescription":"Created for GBM Pembro HSPPC protocol as requested by Y. Yakovlev. mc 12/19/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"iRANO Criteria for response","type":"Preferred Question Text","description":"iRANO Criteria for response","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44064941-DCF1-3255-E053-F662850A158D","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"COOPERM","dateModified":"2016-12-30","changeDescription":"Created for GBM Pembro HSPPC protocol as requested by Y. Yakovlev. mc 12/19/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}